UAE Heart Failure Treatment Drugs Market, by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and O

UAE Heart Failure Treatment Drugs Market, by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Heart failure is characterized by the inability of the heart to pump adequate amount of blood to the body. There are three types of heart failures; left-sided heart failure, right-sided heart failure, and biventricular heart failure. The condition is treated with particular cardiovascular drugs available in the market. Moreover, the treatment for heart failure depends on the stages (stage A, B, C, & D). Drugs such as diuretics, ACE inhibitors, angiotensin 2 receptor blockers, beta blockers, and digitalis are majorly used in the treatment of heart failure.
Various global players are engaged in development of novel therapies and drugs for treating heart failure. In May 2020, AstraZeneca Pharmaceuticals PLC. Received the U.S. Food and Drug Administration’s approval for Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce risk of cardiovascular death and hospitalization for heart failure.
Key features of the study:
This report provides in-depth analysis of the UAE heart failure treatment drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the UAE heart failure treatment drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Novartis International AG, AstraZeneca Plc., Amgen, Inc., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc., and Teva Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
The UAE heart failure treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the UAE heart failure treatment drugs market.
Detailed Segmentation
UAE Heart Failure Treatment Drugs Market, By Drug Class:
ACE Inhibitors
Angiotensin 2 Receptor Blockers
Beta Blockers
Diuretics
Aldosterone Antagonists
Inotropes
Others
UAE Heart Failure Treatment Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Novartis International AG*
Company Overview
Drug Class Portfolio
Financial Overview
Key Highlights
Market Strategies
AstraZeneca Plc.
Amgen, Inc.
Pfizer, Inc.
Mylan N.V.
Merck & Co., Inc.
Bristol-Myers Squibb
GlaxoSmithKline Plc.
Teva Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.